The company aims to raise up to RON9 million to support strategic investments, especially the development of the research laboratory and microorganism multiplication capacities, the expansion of the irrigation system at the Zimnicea farm, the strengthening of its presence on external markets, as well as ensuring the working capital needed to meet a growing demand for the company’s products.
“The capital market plays an essential role in supporting Norofert’s strategy. The company started trading on the Bucharest Stock Exchange in March 2020, at a valuation of RON24 million, and at the beginning of 2026 its market capitalization had doubled. We have made investments of approximately RON 30 million in development, research, and innovation in almost six years since listing. The share capital increase takes place in the context of expanding operational activity and implementing Norofert’s medium- and long-term development strategy. This operation provides the resources needed to accelerate investments and to strengthen operations in the United States and Brazil, markets with a strategic role in our growth plans. Our objective remains the sustainable development of the company and the creation of long-term value for shareholders,” said Vlad Popescu, Chairman of the Board of Directors of Norofert.
The capital increase was approved by shareholders through Resolution no. 1 of the Extraordinary General Meeting of Shareholders held on October 9, 2025. In the first stage of the operation, existing shareholders will have preemptive rights to subscribe for the new shares. To subscribe for one new Norofert share (NRF) at a price of RON 2.7 per share, are need five preemptive rights. The preemptive rights, symbol NRFR03, are not tradable. The exercise period lasts 10 business days, from 10th of February to 23rd of February 2026.
The shares remaining unsubscribed after the end of the preemptive rights exercise period will be offered for subscription in the second stage through a private placement. The Norofert Board of Directors will set the terms and conditions of this stage. The second stage will end within a maximum of 10 business days from the closing date of the first stage.
Norofert ended the first nine months of 2025 with a turnover of RON29 million, down 18% on the year, and net profit of RON4.5 million, compared to RON1.3 million in the same period of 2024.
Norofert shares have traded 2% higher so far in 2026 and 2% lower over the last 12 months. Valued at RON50 million on the AeRO market, Norofert Group is 34.8%-owned by Vlad Popescu, 12.2% by Marius Alexe and 10.2% by Ileana Popescu.